NLRP3 and coronary artery disorder: Notably, all clinical trials that obtained significant cardiovascular benefits (CANTOS, COLCOT, and LoDoCo2) so far in terms of anti-inflammatory treatment for coronary heart disease target the NLRP3/IL1β inflammatory axis [11–13].